Showing 4761-4770 of 7765 results for "".
- Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meetinghttps://practicaldermatology.com/news/lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting/2457885/Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Tal
- NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastaseshttps://practicaldermatology.com/news/nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases/2457887/NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose esca
- Zylö Therapeutics: Adam Friedman, MD to Present Data at AAD Annual Meetinghttps://practicaldermatology.com/news/zyl-therapeutics-adam-friedman-md-to-present-data-at-aad-annual-meeting/2457886/Zylö Therapeutics, a nanotechnology-based biopharmaceutical company dedicated to bringing innovative technologies to multiple facets of medicine, announced that preclinical data, utilizing Zylö’s patented hydrogel-derived Na
- FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-jemdel-plaque-psoriasis-treatment/2457889/The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved, Jemdel will be the first high-potency topical steroid treatment for plaque psoriasis with dosin
- eRelevance Adds Two to Executive Leadership Teamhttps://practicaldermatology.com/news/erelevance-adds-two-to-executive-leadership-team/2457901/eRelevance has added two new names to its executive leadership team. Rafael Landestoy is now vice president of business development and Travis Skidmore is vice president of client success and retention. Mr. Landestoy will lead eRelevance&nbs
- SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanomahttps://practicaldermatology.com/news/skylinedx-and-mayo-clinic-to-collaborate-on-development-of-diagnostic-tests-for-melanoma/2457903/SkylineDx and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factor
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- Revision to Launch Intellishade TruPhysicalhttps://practicaldermatology.com/news/revision-to-launch-intellishade-truphysical/2457912/Revision Skincare will be launching Intellishade® TruPhysical™, formulated with a proprietary blend of over 20 age-defying ingredients. The four-in-one moisturizer helps to correct, protect, hydrate and shield skin for a brighter, smoother complexion. According to
- Anti-IL22 Therapy May Represent New Treatment Option for Severe ADhttps://practicaldermatology.com/news/researchers-close-in-on-possible-new-treatment-for-severe-ad/2457913/New research suggests that IL-22/Th22 targeting may offer a novel treatment alternative for patients with severe atopic dermatitis (AD). The findings, which appear in the Journal of the American Academy of Dermatology, provide the first e
- Retin-A Micro Gel Microsphere 0.06% Now Available from Ortho Dermatologics to Treat Acnehttps://practicaldermatology.com/news/retin-a-micro-gel-microsphere-006-now-available-from-ortho-dermatologics-to-treat-acne/2457914/Retin-A Micro (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals. The FDA approved Ortho Dermatologics' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgar